Cardiol Therapeutics Files 6-K Report
Ticker: CRDL · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1702123
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, news-release
TL;DR
Cardiol Therapeutics filed a 6-K on 9/10/24 with a news release attached.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on September 10, 2024, to report information for the month of September 2024. The filing includes Exhibit 99.1, which is a news release. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.
Why It Matters
This filing provides an update on Cardiol Therapeutics' corporate activities and news, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- 0001062993-24-016358 (filing_id) — Accession Number
- September 10, 2024 (date) — Filing Date
- Oakville, Ontario, Canada (location) — Principal Executive Offices
FAQ
What type of report is Cardiol Therapeutics filing?
Cardiol Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When was this Form 6-K filed?
The Form 6-K was filed on September 10, 2024.
What is the primary purpose of a Form 6-K filing?
A Form 6-K is used by foreign private issuers to submit information that they have made or are required to make public in their home country, or that they have submitted or will submit to their shareholders.
Where are Cardiol Therapeutics' principal executive offices located?
Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada.
What exhibits are included with this Form 6-K filing?
This Form 6-K filing includes Exhibit 99.1, which is a News Release.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-09-10 07:29:33
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 13KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-016358.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: September 10, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer